Insider · CIK 0001313516
David Emerson Jorden
Files at AURX (Nuo Therapeutics, Inc.). First filing Dec 3, 2025, latest Aug 31, 2026.
In brief
David Emerson Jorden files SEC Form 4 as CEO, CFO and director at AURX (Nuo Therapeutics, Inc.). Since Dec 3, 2025, David Emerson Jorden has reported 1 open-market buy worth $9,539 and 1 open-market sell worth $300k, the latest filed on Aug 31, 2026.
A track record needs three past buys with six months of prices behind them; David Emerson Jorden has 0, so none is measured yet.
The newest scored trade: bought $9,539 of AURX on Aug 27, 2026, filed Aug 31, 2026, scored 28 (weak). In the last 12 months: 1 buy worth $9,539 and 1 sell worth $300k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AURX: Nuo Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | AURXbuy Nuo Therapeutics, Inc. | $9,539 8,773 shares | +0% | +39% from low-67% from high | |
| 39Weak | AURXsell Nuo Therapeutics, Inc. | $300k 200,000 shares | -9% | - |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | AURX Nuo Therapeutics, Inc. | POpen-market purchase Common Stock | +789 | $1.07 | $844 | 2,062,016 | 43 d ago |
| Aug 28, 2026 | AURX Nuo Therapeutics, Inc. | POpen-market purchase Common Stock | +7,984 | $1.09 | $8,695 | 2,070,000 | 43 d ago |
| Aug 27, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +789 | $1.07 | $844 | 2,062,016 | Aug 28, 2026 |
| Aug 28, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +7,984 | $1.09 | $8,695 | 2,070,000 | Aug 28, 2026 |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +162,500 | $1.00 | $163k | 2,222,119 | Jul 2, 2026 |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -160,892 | $1.01 | $163k | 2,061,227 | Jul 2, 2026 |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -162,500 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Option to purchase common stockderivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jun 5, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +13,245 | $1.10 | $15k | 2,085,000 | Jun 5, 2026 |
| Jan 1, 2026 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +125,000 | $0.40 | $50k | 2,071,755 | Jan 5, 2026 |
| Jan 1, 2026 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -25,381 | $1.97 | $50k | 2,046,374 | Jan 5, 2026 |
| Dec 31, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -125,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Nov 28, 2025 | AURX Nuo Therapeutics, Inc. | SOpen-market sale Common Stock | -200,000 | $1.50 | $300k | 1,946,755 | Dec 3, 2025 |
| Aug 1, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +100,000 | $0.40 | $40k | 2,075,358 | Aug 4, 2025 |
| Aug 1, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +92,710 | $0.40 | $37k | 2,168,068 | Aug 4, 2025 |
| Aug 1, 2025 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -21,313 | $1.74 | $37k | 2,146,755 | Aug 4, 2025 |
| Aug 9, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -192,710 | $0.00 | $0 | 0 | Aug 4, 2025 |
Questions about David Emerson Jorden
Answered from the filings on this page, as of the latest one.
Is David Emerson Jorden buying or selling?
In the last 12 months David Emerson Jorden reported 1 open-market buy worth $9,539 and 1 open-market sell worth $300k on SEC Form 4; the latest was bought $9,539 of AURX on Aug 27, 2026. Grants, option exercises and tax withholding are not counted.
How did David Emerson Jorden's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Emerson Jorden has 0.
Where does David Emerson Jorden file Form 4?
David Emerson Jorden has filed Form 4 at AURX (Nuo Therapeutics, Inc.) as CEO/CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.